Marwah Medicine

COPD, FMGE, INICET, NEET PG

COPD: Long Term Oxygen Therapy

#NEETPG #FMGE #INICET #COPD 1 minute read Long term oxygen therapy is the only pharmacological intervention that is demonstrated to reduce mortality in patients of Chronic obstructive lung disease. So here is a quick look at indications for LTOT @1L/min for 15 hours per day. Resting sp02 of less than 88% or p02< 55 mm Hg sp02 < 89% (p02 56-59 mm Hg) with Pulmonary artery hypertension sp02 < 89% (p02 56-59 mm Hg) with right sided congestive heart failure sp02 < 89% (p02 56-59 mm Hg) with Erythrocytosis The benefit of mortality reduction is directly proportional to number of hours oxygen is used. Mostly oxygen concentrator is used to ensure good quality of life. Next step for a would be to develop inhouse portable systems in India that allow mobility outside the home. The long-term hypoxia caused pulmonary vasoconstriction that leads to pulmonary artery hypertension. Loud P2, Narrow split S2 are auscultatory findings to be looked out for. Mean pressure >20 mmHg is threshold for diagnosis of PAH. Hypoxia leads to increased RBC count and secondary polycythemia.

INICET, Medical, Medicine, Medicine classes, NExT, NExT Exam

FDA Approves First Oral Drug for Dermatomyositis

Brepocitinib (Lisraya) Explained: Mechanism, VALOR Trial, Dose, Safety & Exam Pearls By Dr Deepak Marwah  |  Marwah Medicine A major change has arrived in dermatomyositis treatment. On August 27, 2026, the US FDA approved brepocitinib (Lisraya) tablets for adults with dermatomyositis, making it the first FDA-approved oral treatment specifically indicated for adult dermatomyositis. HIGH-YIELD ONE-LINER Brepocitinib = oral selective TYK2-JAK1 inhibitor → adult dermatomyositis. For medical students, that one line may be enough to answer a future NEET-PG, INI-CET or FMGE update question. For clinicians, however, the story is more interesting: the Phase 3 VALOR trial showed meaningful improvement in overall dermatomyositis activity, skin disease, physical function and glucocorticoid tapering with the 30-mg dose. Why this approval matters Dermatomyositis is a systemic autoimmune inflammatory myopathy. The classic teaching focuses on proximal muscle weakness, heliotrope rash and Gottron papules, but clinically the disease may involve skin, muscle, joints, lungs and other organs. Treatment has traditionally relied heavily on glucocorticoids and other immunomodulatory therapies, many used off-label. A specifically approved oral targeted therapy therefore represents an important change in the treatment landscape. What exactly is brepocitinib? Brepocitinib is an oral selective inhibitor of TYK2 and JAK1. These kinases participate in intracellular cytokine signaling pathways involved in immune activation and inflammation. Think of the pathway as: Cytokine signal → JAK/TYK signaling → inflammatory gene signaling → immune-mediated tissue injury. By inhibiting TYK2 and JAK1, brepocitinib modifies several inflammatory signaling pathways implicated in dermatomyositis. The study behind the approval: VALOR The pivotal evidence came from the Phase 3 VALOR trial, a double-blind randomized placebo-controlled study involving 241 adults with dermatomyositis. Participants received brepocitinib 30 mg once daily, brepocitinib 15 mg once daily, or placebo for 52 weeks. Background standard therapies were continued and glucocorticoids were tapered. What did the trial show? Group Mean Total Improvement Score at Week 52 Brepocitinib 30 mg 46.5 Brepocitinib 15 mg 37.5 Placebo 31.2 The 30-mg dose was significantly superior to placebo for the primary endpoint. Importantly, brepocitinib 30 mg was also superior across all nine key secondary endpoints, including skin disease activity, systemic glucocorticoid tapering and functional disability. Improvements in some outcomes were observed as early as week 4. It was not just about muscle enzymes One of the clinically attractive aspects of the VALOR results is that benefit was not restricted to a laboratory value. Dermatomyositis can produce persistent and troublesome cutaneous disease even when muscle manifestations are less dramatic. The 30-mg dose demonstrated improvement across clinically relevant domains including skin activity and physical function. The steroid-sparing angle Long-term glucocorticoid exposure carries substantial toxicity, including diabetes, osteoporosis, infection risk, cataracts, hypertension and weight gain. In VALOR, improvement with brepocitinib 30 mg was accompanied by greater glucocorticoid tapering. This makes the result clinically more meaningful than a change in a single disease marker. Does this replace steroids? No. The approval should not be interpreted as meaning that every newly diagnosed patient can simply replace conventional therapy with one tablet. Dermatomyositis is heterogeneous. Treatment decisions still depend on the severity and pattern of muscle disease, dysphagia, respiratory involvement, interstitial lung disease, skin disease, autoantibody profile, malignancy evaluation, previous treatment response and patient-specific risks. Also remember an important trial detail: standard therapies were continued while glucocorticoids were tapered. Brepocitinib adds a new targeted option; it does not erase the need for individualized specialist management. Dose: the number worth remembering The FDA-approved Lisraya tablet contains brepocitinib 30 mg, administered orally once daily for adults with dermatomyositis. Safety: oral does not mean casual Brepocitinib is a potent immunomodulatory therapy. In VALOR, serious infections occurred more frequently with brepocitinib 30 mg than with placebo (10% versus 1%). The FDA prescribing information contains important warnings and precautions, including serious infections, malignancy, major adverse cardiovascular events and thrombosis. Common adverse reactions reported in the FDA medication information include upper respiratory tract infections, headache, fatigue, urinary tract infection, nausea, bronchitis, arthralgia, diarrhea, back pain, falls, influenza and acne. Clinical message: “Oral” should never be confused with “low-risk.” Appropriate patient selection, screening and monitoring remain essential. What should medical students remember? Drug: Brepocitinib Trade name: Lisraya Route: Oral, once daily Dose: 30 mg once daily Mechanism: Selective TYK2-JAK1 inhibitor Indication: Dermatomyositis in adults FDA approval: August 27, 2026 Key trial: VALOR Potential exam question A patient with dermatomyositis is started on a newly FDA-approved oral therapy that selectively inhibits TYK2 and JAK1. Which drug is most likely being prescribed? Answer: Brepocitinib (Lisraya). The bigger lesson: targeted therapy is entering myositis For years, dermatomyositis was taught through its memorable clinical signs: heliotrope rash, Gottron papules and proximal muscle weakness. Those remain fundamental. But modern medicine increasingly asks a second question: which molecular pathways are driving the disease, and can those pathways be targeted? Brepocitinib represents that transition from broad immunosuppression toward more targeted immune modulation. Its ultimate place in treatment algorithms will continue to evolve with real-world experience, longer-term safety data, accessibility and cost. But the 2026 approval itself is already an important milestone in dermatomyositis therapy. Frequently Asked Questions What is the new oral drug for dermatomyositis? Brepocitinib, marketed as Lisraya, was FDA-approved in August 2026 for the treatment of dermatomyositis in adults. What is the mechanism of brepocitinib? Brepocitinib is an oral selective inhibitor of TYK2 and JAK1, modifying cytokine signaling involved in inflammatory and autoimmune pathways. What is the dose of brepocitinib for dermatomyositis? The FDA-approved Lisraya dose is 30 mg orally once daily. Is brepocitinib a JAK inhibitor? Yes. Brepocitinib selectively inhibits TYK2 and JAK1. Is brepocitinib better than steroids for dermatomyositis? The treatments should not be reduced to a simple either-or comparison. In VALOR, background standard therapies were continued while glucocorticoids were tapered. The 30-mg brepocitinib group showed clinical benefit and greater glucocorticoid tapering. What is the most important safety concern? Serious infection risk is important. The FDA label also contains warnings and precautions regarding malignancy, major adverse cardiovascular events and thrombosis. What should NEET-PG and INI-CET students remember? Brepocitinib → oral TYK2-JAK1 inhibitor → adult dermatomyositis. Remember the 30-mg once-daily dose […]

FMGE, INICET, NEET PG, NExT

Anaphylactic Shock and Its Management: A Comprehensive Guide

Anaphylactic shock is the most severe form of allergic reaction and it is characterized by a combination of the following life-threatening symptoms in patient after parenteral drug administration or vaccine. It can occur within seconds to minutes making it a difficult case to handle. Severe Hypotension: As the blood vessels dilate and fluids leak into surrounding tissues, the volume of blood circulating through the body decreases, leading to shock. This can result in the organs not receiving enough oxygen and nutrients, causing them to malfunction. Airway Obstruction: Laryngeal oedema, swelling of the throat or tongue can block the airway, making it difficult to breathe and presents as stridor. This is a critical concern and can lead to respiratory failure without prompt treatment. This is coupled with bronchospasm and wheeze. Loss of Consciousness: Due to low blood pressure and inadequate oxygen supply to the brain, individuals may faint or become unresponsive. Multiple Organ Involvement: Anaphylactic shock can affect vital organs, including the heart, lungs, liver, and kidneys. Without rapid intervention, the situation can quickly become fatal. Common Triggers of Anaphylactic Shock Understanding the common triggers for anaphylaxis is crucial for prevention and management. The most frequent triggers include: Food Allergies: Certain foods, especially peanuts, tree nuts, shellfish, eggs, and milk, are among the most common culprits. These foods can provoke an immune response in individuals with allergies to them. Insect Stings: Bee stings, wasp stings, or bites from other insects like hornets can cause anaphylaxis in people allergic to venom. Medications: Antibiotics (like penicillin) and non-steroidal anti-inflammatory drugs (NSAIDs) can trigger severe allergic reactions in some individuals. Latex: Latex allergies are common, particularly in healthcare settings where gloves and other medical devices made from latex are frequently used. Other Allergens: Although less common, some people may experience anaphylaxis due to allergens like pollen, mold, or animal dander. Symptoms of Anaphylactic Shock The symptoms of anaphylaxis typically occur rapidly after exposure to an allergen. They can range from mild to severe and affect multiple body systems. Common symptoms include: Skin reactions: Hives, itching, redness, or swelling (especially around the eyes, lips, and throat). Respiratory symptoms: Difficulty breathing, wheezing, throat tightness, swelling of the tongue or throat, and hoarseness. Cardiovascular symptoms: Dizziness, fainting, rapid heartbeat (tachycardia), or a drop in blood pressure (hypotension), which may cause shock. Gastrointestinal symptoms: Nausea, vomiting, abdominal cramps, or diarrhea. Neurological symptoms: Anxiety, confusion, and loss of consciousness in severe cases. Management of Anaphylactic Shock Immediate treatment is essential for anaphylactic shock. The following are the primary management strategies to mitigate the effects of anaphylaxis and prevent death: 1. Administer Epinephrine (Adrenaline) The first and most critical step in managing anaphylaxis is to administer epinephrine (adrenaline). Epinephrine is a life-saving medication that works quickly to counteract the severe allergic response. It constricts blood vessels, raises blood pressure, reduces swelling, and helps relax the muscles in the airways, improving breathing. Epinephrine is usually administered through an intramuscular injection, commonly in the thigh. For people at risk of anaphylaxis, carrying an epinephrine auto-injector (e.g., EpiPen) is essential. If you suspect anaphylaxis, inject the epinephrine as soon as possible and seek emergency medical help. 2. Call Emergency Medical Services (EMS) Anaphylaxis can recur, and additional medical intervention may be necessary. Medical personnel can administer further doses of epinephrine, antihistamines, corticosteroids, or other medications to stabilize the individual. 3. Lay the Person Down and Elevate Their Legs If the person is conscious, help them lie down with their legs elevated. This position helps to increase blood flow to vital organs and can prevent fainting or shock. However, if the person is having difficulty breathing, allow them to sit up or find a position that is more comfortable. 4. Administer Antihistamines and Corticosteroids Antihistamines (such as diphenhydramine) can help reduce some of the symptoms of anaphylaxis, such as hives and itching, but they should not replace epinephrine. Corticosteroids may be used to reduce inflammation and prevent the recurrence of symptoms, but they take longer to work and should not be the first line of defense. 5. Oxygen Therapy In severe cases, oxygen may be required to help the person breathe and maintain adequate oxygen levels in the blood. This is typically administered in a medical setting. 6. Observation and Follow-Up Care Even after initial treatment with epinephrine, the person should be observed for at least 4-6 hours in a medical facility. Anaphylaxis can recur, and additional doses of epinephrine may be required. Prevention of Anaphylactic Shock While anaphylactic shock is an emergency, prevention is the best strategy. Here are some tips to minimize the risk of anaphylaxis: Identify and Avoid Triggers: If you know what causes your allergic reactions, avoid those allergens. For example, if you’re allergic to peanuts, make sure to avoid foods that contain peanuts or are processed in facilities that handle peanuts. Carry Epinephrine: Anyone at risk for anaphylaxis should always carry an epinephrine auto-injector. Ensure that it is easily accessible and not expired. Wear Medical Identification: A medical alert bracelet or necklace can inform others about your allergies in case of an emergency. Educate Others: Make sure your family, friends, coworkers, and others know how to recognize the signs of anaphylaxis and how to use an epinephrine auto-injector if necessary. Work with a Healthcare Provider: If you have a history of severe allergic reactions, work with your doctor to develop a personalized action plan. This plan will help you avoid triggers and know what steps to take in the event of an anaphylactic reaction.

FMGE, INICET, Medical

STROKE

DIAGNOSIS For any neurological emergency first secure airway, check BP and calculate NIHSS. National institute of health stroke scale value > 5 confirms stroke Best initial step: Head CT without contrast to differentiate ischemic from hemorrhagic stroke and identify potential candidates for thrombolytic therapy. If CT head is normal and no evidence of CNS bleed in present in symptomatic patient it implies Acute ischemia stroke Labs to draw immediately, in case thrombolytic therapy or intervention may be required, include CBC, Random blood sugar, coagulogram, cardiac biomarkers and KFT CTA is done after fibrinolysis to determine opening of large vessel occlusion Investigations NCCT head ECG Echo Holter Carotid doppler Transcranial doppler Conventional Angiography Common Stroke Symptoms by Vessel Territory  VESSEL TERRITORY  Characteristic features   Middle cerebral artery Patient looks towards the side of lesion Contralateral paresis and sensory loss in the face and arm Homonymous hemianopsia Global Aphasia for dominant lobe lesion Neglect and constructional apraxia for non-dominant lobe lesion   Anterior cerebral artery Contralateral paresis and sensory loss in the leg Aggressive behavior with personality changes Abulia Urinary incontinence Posterior cerebral artery P1 PCA: Weber syndrome I/L 3rd nerve palsy with contralateral hemiparesis   P1 PCA: Nothnagel syndrome I/L 3rd nerve palsy with contralateral limb ataxia Lacunar Pure motor paralysis due to damage to posterior limb of internal capsule Pure sensory stroke Ataxic hemiparesis, dysarthria, or clumsy hand Strokes affecting the thalamus may cause thalamic pain syndrome several weeks after the event, patient complaints of burning pain over hand, arm, leg on even touch   Transient ischemic attack Any 1 of the symptoms above depending on location of vascular lesion and 1.       Neurologic deficit lasts < 24 hours (most last < 1 hour) 2.       DW MRI will be normal   Wallenberg syndrome due to vertebral artery involvement Loss of pain and temperature sensation on ipsilateral face and contralateral body Ipsilateral bulbar weakness Ipsilateral Horner syndrome Vertigo Nystagmus Carotid artery dissection Sudden headache, neck pain, Horner syndrome Treatment of acute ischemic stroke < 6 hours 6 -24 hours Fibrinolysis but BP should be less than < 185/110 mm Hg If BP remains more than the cut off mentioned then Schedule thrombectomy Thrombectomy after conventional cerebral angiography Ideal window period for acute ischemic stroke is 4.5 hours but can be done up to 6 hours Treat fever and hyperglycemia as both are associated with poorer prog- noses in the setting of acute stroke. Monitor for signs and symptoms of brain swelling, raised intracranial pressure and herniation. Treat acutely with mannitol and Prevent and treat poststroke complications, such as aspiration pneumonia, urinary tract infection (UTI), and deep vein thrombosis (DVT). Contraindications to fibrinolysis Stroke or head trauma within the last 3 months Anticoagulation with INR > 1.7 MI in past 3 months Prior intracranial hemorrhage Elevated BP: Systolic > 185 mm Hg or diastolic 110 mm Hg Major Surgery in the past 14 days On discharge the following measures are to be introduced – Hypertension treatment with target BP of < 130/80 mm Hg Keep HbA1c < 7% Statins Acetylsalicylic acid and ticagrelor (dual antiplatelet therapy) For cardioembolic strokes due to atrial fibrillation, target INR is 2-3. In Cases in India involving a prosthetic valve deployed for calcified mitral valve, the target INR is 2.5-3.5. Carotid endarterectomy: If stenosis is > 60% in symptomatic patients or >70% in asymptomatic patients (contraindicated in complete occlusion)

FMGE, INICET, Medical, NEET PG, NEETPG2024

Congenital Heart Disease

#NEETPG #FMGE #INICET Criteria used for diagnosis are NADAS criteria Major Criteria Blue baby with noise in heart is having failure Cyanosis due to R- L shunting. It is central cyanosis non-responsive to oxygen administration Diastolic murmur Systolic murmur grade III or more Congestive heart failure due to L-R to shunting that causes overloading of lung circulation and resultant pulmonary edema     Minor criteria Systolic murmur less than grade III Abnormal S2 like single S2 in TOF Abnormal ECG like Right axis deviation in Ostium Secundum Abnormal CXR like boot shaped heart Abnormal BP like in coarctation of aorta with BP in legs being lower than that in upper limbs     Must know fact Correct answer Leading congenital heart disease Peri-membranous VSD Congenital heart disease that shows spontaneous closure Muscular VSD Leading congenital cyanotic heart disease at day 0 Transposition of great arteries   Ductal dependent pulmonary circulation   TOF Tricuspid atresia TGA Ductal dependent systemic circulation   Aortic atresia Mitral atresia Hypoplastic left heart syndrome Interrupted aortic arch Components of tetralogy of Fallot  Right ventricular outflow tract obstruction Concentric right ventricular hypertrophy VSD Over riding of aorta Triology of Fallot Atrial septal defect Concentric Right ventricular hypertrophy Right ventricular outflow tract obstruction Pentalogy of Fallot Right ventricular outflow tract obstruction Concentric right ventricular hypertrophy VSD Over-riding of aorta ASD Ebstein anomaly Lithium intake by mother Inferior displacement of tricuspid valve Tricuspid regurgitation Associated with WPW syndrome Alprostadil is contraindicated in Truncus arteriosus Total anomalous pulmonary venous connection Central cyanosis on day 0 which worsens on crying Congenital diaphragmatic hernia Central cyanosis on day 0 which improves on crying Choanal atresia

INICET, NEET PG, NEET PG 2025

Bartter Syndrome vs. Gitelman Syndrome: A Must-Know Topic for NEET PG & INI-CET Aspirants

When preparing for NEET PG and INI-CET, mastering renal tubular disorders is crucial. Among these, Bartter Syndrome and Gitelman Syndrome are frequently tested due to their importance in clinical practice. Understanding their pathophysiology, clinical presentation, and lab findings with precision is essential for scoring high in medical entrance exams. Pathophysiology in a Nutshell Bartter Syndrome mimics the effect of chronic loop diuretics (e.g., furosemide), leading to salt-wasting and hypokalemia. Gitelman Syndrome mimics thiazide diuretics, causing hypokalemia, hypomagnesemia, and hypocalciuria. Clinical Case Example Case 1 Case 2 A 3-month-old infant presents with failure to thrive, polyuria, and hypokalaemia. Urinary calcium is high. Think Bartter Syndrome 15-year-old presents with muscle cramps, fatigue. Labs show hypokalaemia, hypomagnesemia and low urinary calcium. Think Gitelman Syndrome.   These clinical and biochemical differences should be memorized thoroughly to answer exam questions accurately. Bookmark this page on marwahMedicine.com for your last-minute revision!

FMGE, INICET, Medical, Medicine, NEET PG, NEETPG2024

Tricuspid Stenosis

Tricuspid stenosis Key pick up points –        Large a waves in JVP –        Blunted Y descent in JVP –        Mid-diastolic murmur –        Pulsations in liver Tricuspid stenosis can coexist with mitral stenosis and usually manifests after the Percutaneous mitral valvotomy has been done. Patient will develop features of right sided heart failure. Symptoms  Ankle edema Abdominal fullness and discomfort Fatigue and effort intolerance Examination findings Large a wave in JVP Blunted y descent Pulsatile liver (Pre-systolic pulsations of liver) Mid diastolic murmur that increases on deep inspiration. It is best heard at Left lower sternal border in tricuspid area Work up ECG shows evidence of left atrial enlargement with P pulmonale and right axis deviation Echo shows thickened tricuspid valve. Severe tricuspid stenosis is size less than 1 cm and transit time across narrowed valve of > 190 msec. CXR show Enlarged Right atria and dilated Superior vena cava along with azygoz vein Treatment Salt restricted diet Diuretics Valve repair or prosthetic valve deployment #NEETPG #FMG #INICET

INICET, NEET PG, NEET PG 2025

Triple therapy in respiratory system: Must Know for NEET PG and INICET aspirants

Triple therapy term is used in management of pulmonary artery hypertension, COPD and cystic fibrosis. Let us now read in next 2 minutes a quick recap of this must asked topic for your forthcoming competitive examinations. Triple Therapy for Pulmonary Arterial Hypertension (PAH) Endothelin Receptor Antagonists (ERAs) Example: Bosentan, Ambrisentan, Macitentan Action: Blocks endothelin, a vasoconstrictor, to reduce pulmonary vascular resistance. Phosphodiesterase-5 (PDE-5) Inhibitors or Soluble Guanylate Cyclase (sGC) Stimulators Example (PDE-5): Sildenafil, Tadalafil Example (sGC stimulator): Riociguat Action: Increases nitric oxide (NO) signaling to promote vasodilation. Prostacyclin Analogues or Prostacyclin Receptor Agonists Example: Epoprostenol, Treprostinil, Selexipag Action: Mimics prostacyclin to dilate blood vessels and inhibit platelet aggregation. This combination targets multiple pathways involved in PAH pathophysiology, offering better control of the disease. Triple Therapy for COPD Triple therapy for Chronic Obstructive Pulmonary Disease (COPD) involves a combination of inhaled medications to manage symptoms and reduce exacerbations. Long-Acting Beta-2 Agonists (LABA) Example: Salmeterol, Formoterol, Indacaterol Action: Broncho dilates airways for symptom relief and improved airflow. Long-Acting Muscarinic Antagonists (LAMA) Example: Tiotropium, Glycopyrrolate, Umeclidinium Action: Reduces bronchoconstriction by blocking muscarinic receptors in the airways. Inhaled Corticosteroids (ICS) Example: Budesonide, Fluticasone, Beclomethasone Action: Reduces airway inflammation and frequency of exacerbations. Triple therapy (LABA + LAMA + ICS) is recommended for patients with moderate to severe COPD who have frequent exacerbations despite dual therapy. Triple Therapy for Cystic Fibrosis (CF) For patients with Cystic Fibrosis, triple therapy specifically refers to the combination of CFTR modulators targeting different aspects of the CFTR protein defect (commonly associated with the F508del mutation). Elexacaftor Action: Facilitates the movement of defective CFTR protein to the cell surface. Tezacaftor Action: Improves CFTR protein processing and stability. Ivacaftor Action: Potentiates the function of the CFTR protein at the cell surface, enhancing chloride ion transport. This combination therapy significantly improves lung function and quality of life in CF patients with the F508del mutation. For more insightful information keep this page bookmarked. You can also check out this link https://marwahmedicine.com/newsite/bartter-syndrome-vs-gitelman-syndrome-a-must-know-topic-for-neet-pg-ini-cet-aspirants/

FMGE, INICET, Medicine, Medicine classes, NEET, NEET PG, NEETPG2024

Tricuspid Regurgitation

#CausesofTricuspid #TricuspidRegurgitation #TricuspidPrevent Causes of Tricuspid Regurgitation Mnemonic: Functional REP-C Functional dilatation of tricuspid annulus due to RVF R: Rheumatic heart disease, Radiation E: Endomyocardial fibroelastosis and Ebstein anomaly (Lithium teratogenicity) P: Pulmonary artery hypertension severe causing RVF P: Pacing lead induced damage C: Carcinoid syndrome   Clinical features Effort intolerance due to less pulmonary blood flow Visible neck pulsations Abdominal fullness and reduced appetite Examination findings Lancisi sign / cv wave/ prominent v waves Absent x descent Prominent y descent (Contrast with blunted Y of tricuspid stenosis) Pulsatile liver (Systolic pulsations) Pan-systolic murmur that increases on deep inspiration ( carvallo sign) Work up ECG shows -Right axis deviation -Right atrial enlargement of P pulmonale -WPW syndrome can co-exist in Ebstein anomaly and hence ECG findings of delta  wave with short PR interval can be present CXR shows RV enlargement IOC is trans-esophageal echocardiography Doppler shows reversed systolic flow in liver Management Salt restricted diet Diuretics Tricuspid valve repair (TVRp) Tricuspid valve replacement (TVR)

INICET, NEET PG

Serum Albumin Ascites Gradient

SAAG value assessment is a common topic asked in NEET PG and INICET. Here is a quick table to remember causes of high SAAG ascites > 1.1 gm / dl . most of the time the question will be on early or late Budd Chiari syndrome. Go crush this in next 30 seconds. Mnemonic: CHIMP  

Scroll to Top